Cargando…

Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer

Background: In 2007, Australia introduced a national human papillomavirus (HPV) vaccination program. In 2017, the onset of cervical screening changed from 18 to 25 years of age, utilising human papillomavirus (HPV) nucleic acid testing. The objective of the study is to describe the HPV genotypes and...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayasinghe, Yasmin L., Tabrizi, Sepehr N., Stevens, Matthew, Leong, Trishe Y-M., Pyman, Jan, Grover, Sonia R., Garland, Suzanne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051959/
https://www.ncbi.nlm.nih.gov/pubmed/36986373
http://dx.doi.org/10.3390/pathogens12030451
_version_ 1785015016844427264
author Jayasinghe, Yasmin L.
Tabrizi, Sepehr N.
Stevens, Matthew
Leong, Trishe Y-M.
Pyman, Jan
Grover, Sonia R.
Garland, Suzanne M.
author_facet Jayasinghe, Yasmin L.
Tabrizi, Sepehr N.
Stevens, Matthew
Leong, Trishe Y-M.
Pyman, Jan
Grover, Sonia R.
Garland, Suzanne M.
author_sort Jayasinghe, Yasmin L.
collection PubMed
description Background: In 2007, Australia introduced a national human papillomavirus (HPV) vaccination program. In 2017, the onset of cervical screening changed from 18 to 25 years of age, utilising human papillomavirus (HPV) nucleic acid testing. The objective of the study is to describe the HPV genotypes and HPV16 variants in biopsies from women ≤ 25 years of age with cervical carcinoma (CC) (cases), compared with those aged >25 years (controls), in a pre-vaccination cohort. Methods: HPV genotyping of archival paraffin blocks (n = 96) was performed using the INNO-LiPA HPV Genotyping assay. HPV16-positive samples were analysed for variants by type-specific PCR spanning L1, E2 and E6 regions. Results: HPV16 was the commonest genotype in cases (54.5%, 12/22) and controls (66.7%, 46/69) (p = 0.30), followed by HPV18 (36.3%, 8/22 vs. 17.3% 12/69, respectively) (p = 0.08). Furthermore, 90% (20/22) of cases and 84.1% (58/69) of controls were positive for HPV16 or 18 (p = 0.42); 100% (22/22) of cases and 95.7% (66/69) of controls had at least one genotype targeted by the nonavalent vaccine (p = 0.3). The majority of HPV16 variants (87.3%, 48/55) were of European lineage. The proportion of unique nucleotide substitutions was significantly higher in cases (83.3%, 10/12) compared with controls (34.1%, 15/44), (p < 0.003, χ(2), OR 9.7, 95%CI 1.7–97.7). Conclusions: Virological factors may account for the differences in CCs observed in younger compared with older women. All CCs in young women in this study had preventable 9vHPV types, which is important messaging for health provider adherence to new cervical screening guidelines.
format Online
Article
Text
id pubmed-10051959
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100519592023-03-30 Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer Jayasinghe, Yasmin L. Tabrizi, Sepehr N. Stevens, Matthew Leong, Trishe Y-M. Pyman, Jan Grover, Sonia R. Garland, Suzanne M. Pathogens Article Background: In 2007, Australia introduced a national human papillomavirus (HPV) vaccination program. In 2017, the onset of cervical screening changed from 18 to 25 years of age, utilising human papillomavirus (HPV) nucleic acid testing. The objective of the study is to describe the HPV genotypes and HPV16 variants in biopsies from women ≤ 25 years of age with cervical carcinoma (CC) (cases), compared with those aged >25 years (controls), in a pre-vaccination cohort. Methods: HPV genotyping of archival paraffin blocks (n = 96) was performed using the INNO-LiPA HPV Genotyping assay. HPV16-positive samples were analysed for variants by type-specific PCR spanning L1, E2 and E6 regions. Results: HPV16 was the commonest genotype in cases (54.5%, 12/22) and controls (66.7%, 46/69) (p = 0.30), followed by HPV18 (36.3%, 8/22 vs. 17.3% 12/69, respectively) (p = 0.08). Furthermore, 90% (20/22) of cases and 84.1% (58/69) of controls were positive for HPV16 or 18 (p = 0.42); 100% (22/22) of cases and 95.7% (66/69) of controls had at least one genotype targeted by the nonavalent vaccine (p = 0.3). The majority of HPV16 variants (87.3%, 48/55) were of European lineage. The proportion of unique nucleotide substitutions was significantly higher in cases (83.3%, 10/12) compared with controls (34.1%, 15/44), (p < 0.003, χ(2), OR 9.7, 95%CI 1.7–97.7). Conclusions: Virological factors may account for the differences in CCs observed in younger compared with older women. All CCs in young women in this study had preventable 9vHPV types, which is important messaging for health provider adherence to new cervical screening guidelines. MDPI 2023-03-13 /pmc/articles/PMC10051959/ /pubmed/36986373 http://dx.doi.org/10.3390/pathogens12030451 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jayasinghe, Yasmin L.
Tabrizi, Sepehr N.
Stevens, Matthew
Leong, Trishe Y-M.
Pyman, Jan
Grover, Sonia R.
Garland, Suzanne M.
Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer
title Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer
title_full Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer
title_fullStr Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer
title_full_unstemmed Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer
title_short Pre-Vaccination Human Papillomavirus Genotypes and HPV16 Variants among Women Aged 25 Years or Less with Cervical Cancer
title_sort pre-vaccination human papillomavirus genotypes and hpv16 variants among women aged 25 years or less with cervical cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051959/
https://www.ncbi.nlm.nih.gov/pubmed/36986373
http://dx.doi.org/10.3390/pathogens12030451
work_keys_str_mv AT jayasingheyasminl prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer
AT tabrizisepehrn prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer
AT stevensmatthew prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer
AT leongtrisheym prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer
AT pymanjan prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer
AT groversoniar prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer
AT garlandsuzannem prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer
AT prevaccinationhumanpapillomavirusgenotypesandhpv16variantsamongwomenaged25yearsorlesswithcervicalcancer